Department of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC.
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.
Am J Kidney Dis. 2018 Oct;72(4):569-581. doi: 10.1053/j.ajkd.2018.02.351. Epub 2018 Apr 11.
Genetic testing is used for screening, diagnosis, and prognosis of diseases consistent with a genetic cause and to guide drug therapy to improve drug efficacy and avoid adverse effects (pharmacogenomics). This In Practice review aims to inform about DNA-related genetic test availability, interpretation, and recommended clinical actions based on results using evidence from clinical guidelines, when available. We discuss challenges that limit the widespread use of genetic information in the clinical care setting, including a small number of actionable genetic variants with strong evidence of clinical validity and utility, and the need for improving the health literacy of health care providers and the public, including for direct-to-consumer tests. Ethical, legal, and social issues and incidental findings also need to be addressed. Because our understanding of genetic factors associated with disease and drug response is rapidly increasing and new genetic tests are being developed that could be adopted by clinicians in the short term, we also provide extensive resources for information and education on genetic testing.
基因检测用于筛查、诊断和预测符合遗传原因的疾病,并指导药物治疗以提高药物疗效和避免不良反应(药物基因组学)。本实践综述旨在根据临床指南中的证据,就基于 DNA 的相关遗传检测的可用性、解释和推荐的临床操作提供信息,这些指南在可用时会被使用。我们讨论了限制遗传信息在临床护理环境中广泛应用的挑战,包括具有明确临床有效性和实用性的少数可操作遗传变异,以及需要提高医疗保健提供者和公众的健康素养,包括直接面向消费者的检测。还需要解决伦理、法律和社会问题以及偶然发现。由于我们对与疾病和药物反应相关的遗传因素的理解正在迅速增加,并且正在开发新的遗传检测方法,这些方法可能会在短期内被临床医生采用,因此我们还提供了广泛的遗传检测信息和教育资源。